Clear Cell Renal Cell Carcinoma
📧 Sign up to get email alerts when something new happens for Clear Cell Renal Cell Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC) [Phase 2]
A randomized Phase 2 trial in first-line advanced renal cell carcinoma compares nivolumab with ipilimumab plus relatlimab versus nivolumab w…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma [Phase 2]
An open-label Phase 2 trial compares the combination of SLC-3010 with Axitinib versus Axitinib alone as second-line therapy for locally adva…
-
CLINICAL_TRIALS research · 2026-03-11Clinical Trial Update: Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma [Phase 1]
Announces an open-label Phase 1/2 study of NEO-811 for locally advanced or metastatic non-resectable clear cell renal cell carcinoma, curren…
-
CLINICAL_TRIALS research · 2026-03-11Clinical Trial Update: CAIX PET/CT for Residual or Recurrent Post-ablative ccRCC [Phase 2]
Phase 2 clinical trial evaluating CAIX-targeted PET/CT imaging for residual or recurrent post-ablative clear cell renal cell carcinoma; the …
-
CLINICAL_TRIALS research · 2026-03-10Clinical Trial Update: A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC [Phase 3]
Phase 3 clinical trial evaluating Volrustomig with or without Casdatifan against Nivolumab plus Ipilimumab as first-line treatment for advan…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-03-10Clinical Trial Update: Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatment [Phase 2]
Phase 2 trial evaluating pembrolizumab plus lenvatinib in recurrent clear cell renal cell carcinoma patients who failed prior adjuvant thera…
-
CLINICAL_TRIALS research · 2026-03-05Clinical Trial Update: Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer [Phase 2]
This Phase 2 clinical trial compares lenvatinib plus everolimus versus cabozantinib for second- or third-line treatment of metastatic clear …
-
CLINICAL_TRIALS research · 2026-03-05Clinical Trial Update: CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer [Phase 1]
Phase 1 trial evaluating CBM588 in combination with nivolumab and cabozantinib for advanced or metastatic renal cell carcinoma.
-
CLINICAL_TRIALS research · 2026-03-05Clinical Trial Update: Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma [Phase 1]
Xencor's XmAb®819 is being studied in a Phase 1 trial for advanced clear cell renal cell carcinoma and the study is currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma [Phase 2]
This clinical trial update describes a Phase 2 study evaluating the combination of cemiplimab and fianlimab in people with clear cell renal …
-
CLINICAL_TRIALS research · 2026-03-02Clinical Trial Update: Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma [Phase 2]
Phase 2 clinical trial evaluating cemiplimab alone or in combination with fianlimab after stereotactic body radiotherapy in patients with cl…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating pazopanib hydrochloride in combination with bevacizumab for previously untreated metastatic renal cell…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer [Phase 1]
Phase 1 clinical trial evaluating nivolumab and ipilimumab, with or without the EXL01 live biotherapeutic product, for metastatic renal cell…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer
A Mayo Clinic-led clinical trial is evaluating whether tumor-derived extracellular vesicles can noninvasively classify different kidney canc…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma [Phase 2]
This is a Phase II trial update for Ivonescimab in previously treated patients with advanced clear cell renal cell carcinoma, and the study …
-
CLINICAL_TRIALS research · 2026-02-24Clinical Trial Update: 177LuPSMA in Renal Cell Carcinoma [Phase 2]
Phase 2 trial evaluating Lutetium-177 labeled PSMA radioligand (177Lu-PSMA) in advanced renal cell carcinoma. The study is currently active …
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC [Phase 2]
Phase 2 neoadjuvant trial evaluating the combination of iparomlimab and tuvonralimab (QL1706) with lenvatinib for clear cell renal cell carc…
-
CLINICAL_TRIALS research · 2026-02-04Clinical Trial Update: Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC [Phase 2]
Phase 2 trial evaluating pucotenlimab in combination with vorolanib as neoadjuvant therapy for clear cell renal cell carcinoma is currently …
-
CLINICAL_TRIALS research · 2026-01-14Clinical Trial Update: Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer [Phase 2]
Phase 2 trial evaluating nivolumab in combination with 177Lu-girentuximab for renal cell carcinoma is currently active but not recruiting.
-
CLINICAL_TRIALS research · 2026-01-05Clinical Trial Update: Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE) [Phase 2]
Phase II neoadjuvant trial in clear cell renal cell carcinoma comparing single-agent belzutifan or pembrolizumab versus their combination. T…
-
CLINICAL_TRIALS research · 2025-12-24Clinical Trial Update: Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study
A Mayo Clinic-led INQUIRE study is identifying novel high-quality methylated DNA markers for renal tumors. The project uses whole-methylome …
-
CLINICAL_TRIALS research · 2025-12-17Clinical Trial Update: Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer [Phase 2]
Phase 2 trial evaluating axitinib with or without the anti-OX40 antibody PF-04518600 for metastatic renal cell carcinoma, currently active a…
-
CLINICAL_TRIALS research · 2025-12-15Clinical Trial Update: A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body [Phase 1, Phase 2]
First-in-human Phase 1/2 trial evaluating REGN10597 alone or with cemiplimab in adults with melanoma, clear-cell renal cell carcinoma, and o…
-
CLINICAL_TRIALS research · 2025-12-11Clinical Trial Update: Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy [Phase 2]
Phase 2 clinical trial update evaluating iparomlimab and tuvonralimab in combination with lenvatinib or axitinib for locally advanced or met…
-
CLINICAL_TRIALS research · 2025-12-10Clinical Trial Update: Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab [Phase 1, Phase 2]
Phase 1/2 trial of Seleno-L Methionine with Axitinib and Pembrolizumab for clear cell renal cell carcinoma, including metastatic disease, is…